Stock Price

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

Capstone retired 75% of its dilutive convertible notes, a major milestone. But with a low stock price and reliance on an equity line, is this a true pivot?

As Ibotta executives head to Wall Street, the real story isn't just their financials, but how their pay-for-sale network is rewriting CPG marketing rules.

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

As Nasdaq threatens delisting, Hub Group's $870M meltdown reveals more than accounting errors—it's a stark lesson in corporate governance.

AstroNova's move to go private via a buyout by Arcline Investment Management is more than a premium exit; it's a strategic play in the high-stakes world of mission-critical industrial technology.

A routine tender offer extension for a small healthcare operator reveals a larger story of a struggling company, a persistent buyer, and a new regulatory era.

A HK$120M venture signals a major shift in the GBA's cold chain. We dissect the tech, the money, and the competitive risks of this ambitious play.

Abundia's new stock buyback isn't just about shareholder value. It's a complex maneuver to restructure debt, fight off market skepticism, and ensure survival.

loanDepot touts major operational growth, yet its stock faces delisting from the NYSE. A deep dive into the company's fight for survival.

Andersen Group insiders cashed out $216.8M in a secondary offering. The company saw no cash, but the move signals market confidence and reshapes its future.

Vertical farming pioneer Agroz Inc. faces expulsion from Nasdaq, a crisis that exposes the harsh financial realities behind the promising agritech revolution.

Tactical Resources debuts on Nasdaq, promising a 'clean' path to rare earth security. But can its Texas project rewrite the rules for a toxic industry?

With shares in OpenAI and a huge stash of Worldcoin, Eightco is buying back its stock. Is it a signal of deep value or a high-risk bet on the AI future?

TerraVest doubles down on its own stock with a massive buyback, calling it undervalued. But with rising debt and an aggressive M&A strategy, is this a shrewd move or a risky bet?

A California union launched a website attacking a private equity firm's investment history, signaling a new, aggressive tactic in the fight to organize workers.

Activist investor Oasis Management, holding 19.5% of Kakaku.com, rejects a board-backed buyout offer, demanding a higher price and igniting a fierce debate.

Japan's Metaplanet is acquiring Super League to create 'Superplanet,' a Nasdaq-listed Bitcoin treasury, in a bold move to tap U.S. capital markets.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

Diodes Inc. secures a massive, interest-free war chest. While markets flinched at the news, the move reveals a calculated strategy for acquisitions and growth.